drugset / Trial / NCT00295503
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Phase 2
Completed
53 enrolled
University of Texas Southwestern Medical Center
Columbia University · collabDuke University · collabUniversity of Chicago · collab
NaSingle-groupOpen-labelTreatment
Summary
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Timeline
- Start
- 2006-02
- Primary completion
- 2010-06
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |